Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

📖 Wiki Page

therapeutic1258 wordssynced 2026-04-02

Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

...

Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Brand Name</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Leqembi</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Kisunla</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Aduhelm</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>CDR-SB Slowing</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>27% (0.45 pts)</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>29-35% (iADRS)</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Marginal</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>None</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>None</td>
</tr>
<tr>
<td class="label">SAR228810</td>
<td>TBD</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>ARIA-E Risk</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Moderate (12.6%)</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Higher (24%)</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>High (~35%)</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>High</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Low (~10%)</td>
</tr>
<tr>
<td class="label">SAR228810</td>
<td>TBD</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>All Anti-Amyloid Therapies</td>
</tr>
<tr>
<td class="label">Disease stage</td>
<td>Early AD (MCI-mild)</td>
</tr>
<tr>
<td class="label">Amyloid confirmation</td>
<td>Required</td>
</tr>
<tr>
<td class="label">Tau imaging</td>
<td>Recommended</td>
</tr>
<tr>
<td class="label">Age</td>
<td>Generally <85</td>
</tr>
<tr>
<td class="label">ApoE4 status</td>
<td>Risk factor for ARIA</td>
</tr>
<tr>
<td class="label">Anticoagulation</td>
<td>Caution</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Annual Cost (est.)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>~$28,000</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>~$32,000</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>~$28,000</td>
</tr>
</table>

Anti-amyloid immunotherapies represent a major therapeutic approach in Alzheimer's disease, targeting the amyloid-beta (Aβ) protein that is central to the amyloid hypothesis. This comparison matrix provides detailed information on six key immunotherapies: Lecanemab (Leqembi), Donanemab (Kisunla), Aducanumab (Aduhelm), Gantenerumab, Crenezumab, and SAR228810.

Overview Comparison Matrix

Mermaid diagram (expand to render)

Detailed Comparison by Therapy

1. Lecanemab (Leqembi)

Mechanism of Action:
Lecanemab is a humanized IgG1 monoclonal antibody that selectively binds to Aβ protofibrils (soluble aggregated Aβ) with high affinity. It clears both protofibrils and plaques through Fc-mediated antibody-dependent cellular cytotoxicity (ADCC).

Target: Aβ protofibrils (soluble aggregates) and existing plaques

Phase 3 Trial - CLARITY-AD:

Patient population: Early AD (MCI due to AD or mild AD dementia) with confirmed amyloid pathology
Treatment duration: 18 months
Primary endpoint: Change in CDR-SB: -0.45 vs placebo (27% slowing)
Secondary endpoints: Amyloid PET SUVr reduction, ADAS-Cog14, ADCOMS
Key results: Significant reduction in brain amyloid (Centiloids decrease), slowed clinical decline

FDA Status: Full approval (2023); covered by Medicare with evidence requirements

ARIA Incidence:

ARIA-E (edema): ~12.6%
ARIA-H (hemorrhage): ~17.3%
Most cases mild to moderate, manageable with monitoring

Dosing Protocol:

10 mg/kg IV infusion every 2 weeks
Requires MRI monitoring at baseline, then weeks 5, 13, 27, 53

Patient Selection Criteria:

Early AD (MCI or mild dementia)
Confirmed amyloid pathology (PET or CSF)
MMSE score 22-30
No contraindication to MRI

-ApoE4 carrier status affects risk assessment

2. Donanemab (Kisunla)

Mechanism of Action:
Donanemab is a monoclonal antibody that targets a specific conformational epitope on Aβ plaques. It binds to Aβ plaques and recruits microglia for plaque clearance through the brain's innate immune system.

Target: N-terminally truncated Aβ plaques (pyroglutamate-modified Aβ)

Phase 3 Trial - TRAILBLAZER-ALZ 2:

Patient population: Early symptomatic AD with low/medium tau pathology
Treatment duration: Up to 76 weeks (with optional treatment suspension)
Primary endpoint: Change in iADRS: -6.02 vs placebo (35.1% slowing)
Secondary endpoints: CDR-SB, amyloid PET, tau PET
Key results: Most robust amyloid removal in class; possible treatment discontinuation after plaque clearance

FDA Status: Full approval (2024)

ARIA Incidence:

ARIA-E: ~24%
ARIA-H: ~31%
Higher than Lecanemab, but most manageable

Dosing Protocol:

350 mg infusion every 4 weeks (ramp-up: 3 initial doses at 700 mg then reduce)
MRI monitoring at baseline, weeks 4, 12, 24, 52, then annually

Patient Selection Criteria:

Early AD with confirmed amyloid
Tau imaging (low/medium tau optimal benefit)
Not recommended for rapid progressors

3. Aducanumab (Aduhelm)

Mechanism of Action:
Aducanumab is a human IgG1 monoclonal antibody that binds to multiple forms of Aβ, including monomers, oligomers, and plaques. It was designed to engage the immune system to clear amyloid plaques.

Target: Aβ plaques (broad-spectrum)

Phase 3 Trials - EMERGE and ENGAGE:

Mixed results; EMERGE showed positive results at high dose
Primary endpoint: CDR-SB change (delayed in EMERGE, not significant in ENGAGE at prespecified analysis)
Key result: Amyloid removal significant but clinical benefit debated
Re-analysis: Suggested benefit in higher dose arm

FDA Status: Withdrawn from market (2024) - manufacturer discontinued commercial availability

Note: Historic importance in field; raised bar for future approvals

4. Gantenerumab

Mechanism of Action:
Gantenerumab is a fully human IgG1 monoclonal antibody that binds with high affinity to Aβ plaques. It engages microglia-mediated clearance but showed limited efficacy in trials.

Target: Aβ plaques

Phase 3 Trials - GRADUATE 1 and 2:

No significant clinical benefit in primary endpoints
High rates of ARIA (brain edema and microhemorrhages)

-did not meet primary endpoints for cognitive benefit

FDA Status: Not approved; development discontinued

Note: Demonstrated amyloid removal but insufficient efficacy

5. Crenezumab

Mechanism of Action:
Crenezumab is a humanized IgG4 monoclonal antibody that preferentially targets Aβ oligomers and protofibrils. The IgG4 isotype reduces Fc-mediated effector functions, theoretically reducing ARIA risk.

Target: Aβ oligomers (soluble aggregated Aβ)

Phase 3 Trials - CREAD and CREAD2:
-did not meet primary endpoints

No significant delays in clinical decline
Lower ARIA rates than other antibodies

FDA Status: Not approved; development discontinued

Note: Interesting proof-of-concept for oligomer-targeting

6. SAR228810

Mechanism of Action:
SAR228810 is a monoclonal antibody targeting Aβ protofibrils with high specificity. Development focused on early AD prevention.

Target: Aβ protofibrils

Phase 1/2 Trials:

Completed early-phase trials
Showed acceptable safety profile
Limited public data on efficacy

FDA Status: Not approved; development status unclear

Clinical Efficacy Comparison

Safety and Risk Profile Comparison

Patient Selection Criteria Summary

Economic and Access Considerations

Alzheimer's Disease

The main [Alzheimer's Disease](/diseases/alzheimers-disease) disease page should reference this comparison matrix for treatment options.

Amyloid Immunotherapy

[Alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy): For comparison with Parkinson's immunotherapies
[Tau Immunotherapy](/therapeutics/tau-immunotherapy): For comparison with tau-targeting approaches

Biomarkers

[Amyloid PET Imaging](/biomarkers/amyloid-pet): For understanding amyloid detection
[p-Tau Biomarkers](/biomarkers/p-tau-217): For understanding patient selection

Clinical Trials

[Clinical Trials in Alzheimer's](/clinical-trials/alzheimers-trials): For trial listings

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Unknown, Lecanemab (Leqembi) - Approved AD Therapy (n.d.)

Unknown, Donanemab Updates (n.d.)

Unknown, Alzheimer's Disease (n.d.)

Unknown, Amyloid PET Biomarkers (n.d.)

Unknown, ARIA (Amyloid-Related Imaging Abnormalities) Mechanisms (n.d.)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — 0.73 · Target: ACSL4
[Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — 0.72 · Target: PVALB
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — 0.70 · Target: TREM2
[GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — 0.64 · Target: GFAP
[Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — 0.63 · Target: SLC17A7

Related Analyses:

[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄

📖 View canonical wiki page →

Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

Overview Comparison Matrix

Detailed Comparison by Therapy

1. Lecanemab (Leqembi)

2. Donanemab (Kisunla)

3. Aducanumab (Aduhelm)

4. Gantenerumab

5. Crenezumab

6. SAR228810

Clinical Efficacy Comparison

Safety and Risk Profile Comparison

Patient Selection Criteria Summary

Economic and Access Considerations

Cross-Linking to Related Content

Alzheimer's Disease

Amyloid Immunotherapy

Biomarkers

Clinical Trials

See Also

External Links

References

Related Hypotheses